BioDiem (ASX:BDM) has secured a divisional patent from China for its novel anti-microbial compound BDM-I.
The patent was granted in China in 2010 for BDM-I, a synthetic compound being developed for the treatment of serious infections.
The Chinese divisional patent gives BioDiem an additional patent application for BDM-I while keeping the priority rights from its original application.
The divisional patent strengthens its portfolio by granting it claims in China for BDM-I and its compounds; the use of BDM-I as a preventive and theapeutic compound against an array of infection; and its effectiveness agains a broad range of micro-organisms, which can cause serious human diseases.
Patent applications for BDM-I have currently been granted in China, Russia, Singapore and Australia, as well as in three of the world’s largest patent jurisdictions, Europe, Japan and the US.
Currently BioDiem is progressing further validation of BDM-I’s antimicrobial activity, conducting further studies to explore the scope of BDM-I’s indications with expanded screening studies, and embarking on a new project in collaboration with Griffith University.
Proactive Investors Australia is the market leader in producing news, articles and research reports on ASX “Small and Mid-cap” stocks with distribution in Australia, UK, North America and Hong Kong / China.
BioDiem bags Chinese patent for its antimicrobial compound
Last updated: 14:00 21 Feb 2013 AEDT, First published: 13:00 21 Feb 2013 AEDT